# US 2020/0390720 A1 · Delivery systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390720 A1
- Document ID: US20200390720A1
- Status: Published application
- Kind: A1
- Application number: 17/007,962
- Filed: 2020-08-31
- Published: 2020-12-17
- Earliest claimed: 2014-10-30
- Assignees: Textile-Based Delivery, Inc.
- Applicants: Textile-Based Delivery, Inc.
- Inventors: David Anderson; Jordan Schindler; Erik Scott Goebel; Nathan Jablonske; Sandy Wood; Michael Drzewinski; Justin Jed
- Web page: https://patentgrep.com/patent/US20200390720A1

## CPC

- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 31/12: Ketones
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 15/24: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof {(A61L15/225 takes precedence)}
- A61L 15/40: containing ingredients of undetermined constitution or reaction products thereof {, e.g. plant or animal extracts}
- A61L 15/44: Medicaments
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/10: Antimycotics
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/43: Hormones, e.g. dexamethasone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for manufacturing drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate may include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. The methods may include disposing a solution including a monomer and an active compound on the substrate. The methods may also include exposing the solution and the substrate to UV light to initiate polymerization of the solution.

## Claims

### Claim 1

A method for manufacturing a drug delivery system, the method comprising:
forming a solution comprising:
a monomer;
an initiator; and
an active compound;
disposing the solution on a substrate, wherein the substrate is selected from a yarn, a yarn precursor, a thread, a filament, and a fiber; and
exposing the solution and the substrate to UV light to initiate polymerization of the solution.

### Claim 2 (depends on 1)

The method of claim 1, wherein the solution further comprises an oligomer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the oligomer is an acrylate stabilizing additive.

### Claim 4 (depends on 1)

The method of claim 1, wherein the active compound is selected from the group consisting of methyl salicylate, ethyl salicylate, arnica oil, peppermint oil, menthol, lidocaine, benzocaine, capsaicin, nonivamide, niacinamide, cannabidiol, caffeine, hydrocortisone, and derivatives thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the monomer is an alkyl methacrylate monomer selected from the group consisting of methyl methacrylate, ethyl methacrylate, n-propyl methacrylate, isopropyl methacrylate, n-butyl methacrylate, t-butyl methacrylate, sec-butyl methacrylate, pentyl methacrylate, 2-ethylhexyl methacrylate, 2-ethylbutyl methacrylate, n-octyl methacrylate, isobornyl methacrylate, isooctyl methacrylate, isononyl methacrylate, and lauryl methacrylate.

### Claim 6 (depends on 1)

The method of claim 1, wherein the monomer is an alkyl methacrylate monomer selected from the group consisting of methyl acrylate, ethyl acrylate, n-propyl acrylate, isopropyl acrylate, n-butyl acrylate, t-butyl acrylate, sec-butyl acrylate, pentyl acrylate, 2-ethylhexyl acrylate, 2-ethylbutyl acrylate, n-octyl acrylate, isobornyl acrylate, isooctyl acrylate, isononyl acrylate, and/or lauryl acrylate

### Claim 7 (depends on 1)

The method of claim 1, wherein the exposing the solution and the substrate to UV light to initiate polymerization of the solution forms a polymerized coating, and wherein the polymerized coating has a glass transition temperature (Tg) selected from a range of between about −60° C. and about 110° C.

### Claim 8 (depends on 1)

The method of claim 1, wherein exposing the solution and the substrate to UV light occurs in a light box comprising one or more inert gases.

### Claim 9 (depends on 8)

The method of claim 8, further comprising twisting a first substrate and a second substrate, wherein the second substrate comprises a greater elasticity than the first substrate.

### Claim 10 (depends on 2)

The method of claim 2, wherein forming the solution further comprises:
(i) mixing the monomer and the oligomer to form the solution;
(ii) warming the monomer and the oligomer mixture between 25° C. and 50° C.;
(iii) adding the initiator to the solution; and
(iv) adding the active compound to the solution.

### Claim 12 (depends on 1)

The method of claim 1, further comprising rewinding the substrate into a bundle after the solution has been polymerized on the substrate.

### Claim 13

A drug delivery system prepared by a process comprising the steps of:
(a) forming a solution comprising:
a monomer;
an initiator; and
an active compound;
(b) disposing the solution on a substrate, wherein the substrate comprises at least one of a yarn, a yarn precursor, a thread, a filament, and a fiber; and
(c) exposing the solution and the substrate to UV light to initiate polymerization of the solution.

### Claim 14 (depends on 13)

The drug delivery system of claim 13, wherein the solution further comprises an oligomer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the oligomer is an acrylate stabilizing additive.

### Claim 16 (depends on 13)

The method of claim 13, wherein the active compound is selected from the group consisting of methyl salicylate, ethyl salicylate, arnica oil, peppermint oil, menthol, lidocaine, benzocaine, capsaicin, nonivamide, niacinamide, cannabidiol, caffeine, and hydrocortisone.

### Claim 17 (depends on 13)

The method of claim 13, wherein the monomer is an alkyl methacrylate monomer selected from the group consisting of methyl methacrylate, ethyl methacrylate, n-propyl methacrylate, isopropyl methacrylate, n-butyl methacrylate, t-butyl methacrylate, sec-butyl methacrylate, pentyl methacrylate, 2-ethylhexyl methacrylate, 2-ethylbutyl methacrylate, n-octyl methacrylate, isobornyl methacrylate, isooctyl methacrylate, isononyl methacrylate, and lauryl methacrylate.

### Claim 18 (depends on 13)

The method of claim 13, wherein the monomer is an alkyl methacrylate monomer selected from the group consisting of methyl acrylate, ethyl acrylate, n-propyl acrylate, isopropyl acrylate, n-butyl acrylate, t-butyl acrylate, sec-butyl acrylate, pentyl acrylate, 2-ethylhexyl acrylate, 2-ethylbutyl acrylate, n-octyl acrylate, isobornyl acrylate, isooctyl acrylate, isononyl acrylate, and/or lauryl acrylate

### Claim 19 (depends on 13)

The method of claim 13, wherein the exposing the solution and the substrate to UV light to initiate polymerization of the solution forms a polymerized coating, and wherein the polymerized coating has a glass transition temperature (Tg) selected from a range of between about −60° C. and about 110° C.

### Claim 20 (depends on 13)

The method of claim 13, wherein the exposure of the solution and the substrate to the UV light results in a cross-linked polymerized coating on the substrate.
